Findings
In this economic evaluation of 89 children with follow-up data from an iBASIS-VIPP randomized clinical trial in Australia, the intervention was estimated to cost A $5131 (US $3607) per child and deliver a cost savings of A $10 695 (US $7519) per child (modeled to age 12 years). In addition, for each dollar invested in treatment, the savings in third-party payer costs was estimated to be A $3.08 (US $3.08).